ArticleThe American journal of case reports2026
Discrepant CD3+ TILs in PD-L1-Negative NSCLC: Favorable Outcome in an Elderly Patient Treated With Nivolumab, Ipilimumab, and Chemotherapy.
Mataichi Sekiya et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.